Genprex, Inc.

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting: ow.ly/8LV250YvMYV #lungcancer #genetherapy

Genprex to Participate at BIO Europe Spring 2026: ow.ly/UTGR50YrO03 #Oncology #Diabetes #GeneTherapy $GNPX

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer: ow.ly/FYPo50Ykblt

Genprex Announces IP Australia’s Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers: ow.ly/yaq250YccwB #genetherapy #lungcancer

Genprex recently announced positive preliminary preclinical data in Type 2 diabetes. Watch this video featuring Genprex's CEO and CMO discussing the new data and what it means: genprex.com/videos/ #genetherapy #diabetes #video $GNPX

Genprex Provides Clinical Update on Diabetes Gene Therapy Program: genprex.com/2026/01/07/gen… #genetherapy #diabetes $GNPX

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies: genprex.com/2026/01/06/gen… #genetherapy #diabetes $GNPX

Data from Genprex’s Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer: ow.ly/8Lkx50XwPnx #genetherapy #lungcancer $GNPX

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials: ow.ly/poAu50Xu29c $GNPX

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers: ow.ly/iEFQ50XtqZh $GNPX

Genprex Announces European Patent Office’s Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer: ow.ly/2AOT50XmpVG $GNPX

Genprex is proud of the preclinical data presented last week at #Targets25 on combining REQORSA with alectinib in ALK positive #NSCLC. To review the poster that was presented in greater detail, click here: ow.ly/vSO950XjVIA

Ananya Banerjee, Ph.D., Post-Doctoral Research Fellow at the Rogel Cancer Center at the University of Michigan, poses with the poster she presented this week at #Targets25. She presented on the preclinical findings on combining REQORSA with alectinib in ALK positive #NSCLC.

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules: ow.ly/xxgs50Xj7Pf $GNPX

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: ow.ly/yQ4n50XiXqI #lungcancer $GNPX

Genprex Announces Registered Direct Offering of up to $8.2 Million Priced At-The-Market Under Nasdaq Rules: ow.ly/9U7n50XgQwH #genetherapy #lungcancer #diabetes $GNPX

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics: genprex.com/2025/10/23/gen… $GNPX

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics: ow.ly/QhSH50XaZG9 $GNPX

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences: ow.ly/lthL50WPwUp $GNPX

$GNPX is passionate about our #diabetes program. We achieved several milestones in 2025 for our diabetes program. For a full overview of the program and more clinical updates, we encourage you to read our recent 2025 letter to stockholders here: ow.ly/NwW850WG4gZ